In Q2 2025, Lyell Immunopharma posted a net loss of $42.7 million, a reduction from the prior year, reflecting disciplined cost management. The company continued clinical advancement of LYL314, initiated a pivotal trial, and secured new funding to extend its runway through mid-2027.

Lyell Immunopharma reported a net loss of $52.2 million for the first quarter ended March 31, 2025, an improvement from a net loss of $60.7 million in the same period of 2024. The decrease in net loss was primarily due to the absence of impairment expenses recognized in the prior year, partially offset by lower interest income. The company's cash, cash equivalents, and marketable securities stood at $330.1 million, which is expected to support operations into 2027.

Lyell Immunopharma reported a significant increase in net loss for the fourth quarter of 2024, primarily driven by acquired in-process research and development expenses and long-lived asset impairment. Despite the financial loss, the company highlighted progress in its clinical pipeline, particularly with IMPT-314, and maintained a strong cash position to fund operations into 2027.

Lyell Immunopharma reported a net loss of $44.6 million for the third quarter ended September 30, 2024, compared to a net loss of $50.9 million for the same period in 2023. The company's cash, cash equivalents and marketable securities totaled $460.7 million as of September 30, 2024, which is expected to fund operations into 2027. Lyell is advancing two wholly-owned product candidates: IMPT-314 is in Phase 1-2 clinical development and LYL119 is entering Phase 1 clinical development.

Lyell Immunopharma reported a net loss of $45.8 million for the second quarter ended June 30, 2024, and has cash, cash equivalents and marketable securities of $491.1 million as of June 30, 2024, which supports advancing diverse pipeline through multiple clinical milestones into 2027.

Lyell Immunopharma reported a net loss of $60.7 million for the first quarter ended March 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $526.3 million as of March 31, 2024, which is expected to fund operations through multiple clinical milestones into 2027.

Lyell Immunopharma reported a net loss of $52.9 million for the fourth quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $562.7 million, expected to fund operations into 2027. Clinical data from lead CAR T-cell and TIL product candidates are expected in 2024, and an IND submission for a second-generation ROR1-targeted CAR T-cell product is planned for the first half of 2024.

Lyell Immunopharma reported a net loss of $50.9 million for the third quarter ended September 30, 2023, compared to a net loss of $70.3 million for the same period in 2022. The company's cash, cash equivalents and marketable securities were $598.2 million as of September 30, 2023, which is expected to fund operations into 2027. They are prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programs

Lyell Immunopharma reported a net loss of $63.9 million for the second quarter ended June 30, 2023, compared to a net loss of $36.3 million for the same period in 2022. The company's cash, cash equivalents, and marketable securities totaled $632.7 million as of June 30, 2023. Initial clinical data from two lead product candidates are expected in 2024.

Lyell Immunopharma reported a net loss of $67.0 million for the first quarter ended March 31, 2023. The company's cash, cash equivalents and marketable securities totaled $668.0 million as of March 31, 2023, which is expected to support operations into 2026.

Lyell Immunopharma reported a net loss of $8.4 million for the fourth quarter of 2022, with revenue of $48.4 million. The company's cash, cash equivalents, and marketable securities totaled $710.3 million as of December 31, 2022, which is expected to fund operations into 2026. Two Phase 1 clinical trials were initiated, and nonclinical data were presented at scientific conferences.

Lyell Immunopharma reported a net loss of $70.3 million for the third quarter ended September 30, 2022. Cash, cash equivalents and marketable securities as of September 30, 2022 were $750.7 million, which extends funding into 2026.

Lyell Immunopharma reported revenue of $35.7 million for the second quarter of 2022, primarily related to the GSK Agreement. The company's cash, cash equivalents, and marketable securities totaled $787.0 million as of June 30, 2022, which is expected to fund operations into 2025.

Lyell Immunopharma reported a net loss of $48.9 million for the third quarter of 2021, compared to a net loss of $35.7 million for the same period in 2020. The company's cash and investments were $936.4 million as of September 30, 2021.

Lyell Immunopharma reported a net loss of $62.6 million for the second quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $974.8 million as of June 30, 2021, including $391.8 million in net proceeds from its initial public offering.